文献速递鼻科

Draf 2B与Draf 3额窦切开术治疗难治性慢性额窦炎疗效相当

Equivalence in outcomes between Draf 2B vs Draf 3 frontal sinusotomy for refractory chronic frontal rhinosinusitis.
PubMed 文献 · Int Forum Allergy Rhinol · 2017-11-13

回顾性队列研究比较双侧Draf 2B(21例)与Draf 3(17例)治疗难治性慢性额窦炎,平均随访15.6个月。两组SNOT-22均显著改善(p=0.0001),Draf 2B组术后1-3个月改善更明显(p=0.003),但5-9个月及末次随访时差异无统计学意义,通畅率、修正手术率及并发症无显著差异。

要点

  • Draf 2B与Draf 3均能持久改善难治性额窦炎症状。
  • Draf 2B术后早期症状改善优于Draf 3。
  • 长期疗效、通畅率、修正率及并发症两组相当。

核心结论

  • Draf 2B与Draf 3手术均能为难治性额窦炎患者提供持久的症状改善。
  • Draf 2B术后早期症状改善更明显,但长期结局与Draf 3相当。

研究设计与样本

  • 回顾性队列研究,比较2000至2016年接受双侧Draf 2B(21例)与Draf 3(17例)手术的患者。
  • 排除肿瘤、不典型增生、黏液囊肿、囊性纤维化或纤毛运动障碍患者。
  • 平均随访时间15.6个月。

主要发现

  • 两组术前疾病参数(既往手术次数、息肉、SNOT-22、额窦Lund-Mackay评分、额窦口前后径、GOSS)均无显著差异。
  • Draf 2B组SNOT-22改善Δ=24.1(p=0.0001),Draf 3组Δ=24.9(p=0.0001)。
  • 术后1至3个月Draf 2B组SNOT-22改善优于Draf 3组(p=0.003)。
  • 术后5至9个月(p=0.66)及末次随访(p=0.90)两组SNOT-22改善程度无显著差异。
  • 两组在窦口通畅率、修正手术率及并发症方面无显著差异。

临床怎么用

  • 对于难治性慢性额窦炎,Draf 2B和Draf 3均可作为有效术式,长期疗效相当。
  • 若期望更早的症状改善,可优先考虑Draf 2B。

局限性

  • 回顾性研究设计。
  • 样本量较小(Draf 2B组21例,Draf 3组17例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Endoscopic Draf 2B and Draf 3 frontal sinusotomies are frequently performed for chronic refractory frontal rhinosinusitis. The purpose of this study was to compare outcomes between Draf 2B and Draf 3 procedures. METHODS: A retrospective cohort study was conducted comparing patients undergoing bilateral Draf 2B vs Draf 3 procedures from 2000 to 2016. Patients with neoplasia, dysplasia, mucocele, cystic fibrosis, or ciliary dyskinesia were excluded. Preoperative disease parameters included number of prior surgeries, presence of polyps, preoperative 22-item Sino-Nasal Outcome Test (SNOT-22) score, frontal Lund-Mackay score, anterior-posterior diameter of the frontal ostium, and Global Osteitis Scoring Scale (GOSS). Postoperative outcomes included SNOT-22 score, neo-ostium patency, surgical revision rates, and complications. RESULTS: A total of 21 patients with bilateral Draf 2B and 17 patients with Draf 3 surgeries were compared. Mean follow-up time was 15.6 months. No significant differences were seen between groups for any preoperative disease parameter. Both cohorts showed statistically significant (p = 0.0001 [Draf 2B]; p = 0.0001 [Draf 3]) and clinically meaningful (Δ = 24.1; Δ = 24.9) improvements in SNOT-22 at last follow-up vs preoperatively. The Draf 2B group had greater improvement in SNOT-22 score than the Draf 3 group at 1 to 3 months (p = 0.003), but the magnitude of improvement equalized at 5 to 9 months (p = 0.66) and last follow-up (p = 0.90). No significant differences were noted between groups regarding patency, revision rates, or complications. CONCLUSION: Both Draf 2B and Draf 3 procedures offer durable symptomatic improvement for patients with refractory frontal CRS. The Draf 2B is associated with earlier postoperative symptom improvement and overall shows comparable long-term outcomes to the Draf 3 sinusotomy.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Patel VS, Choby G, Shih LC, et al. Equivalence in outcomes between Draf 2B vs Draf 3 frontal sinusotomy for refractory chronic frontal rhinosinusitis. Int Forum Allergy Rhinol. 2017. PMID: 29131540. doi:10.1002/alr.22032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。